Top in endocrinology: What to expect during menopause; Novo Nordisk to cut insulin prices
Click Here to Manage Email Alerts
Women often receive information about menopause from family, friends and social media rather than health care providers.
According to Mary Jane Minkin, MD, FACOG, NCMP, physician education about menopause has greatly decreased since 2002. Healio spoke with Minkin and several experts about recent data on menopause what information women should be receiving about it. It was the top story in endocrinology last week.
The second top story was about Novo Nordisk’s announcement that it will cut insulin prices by up to 75% in 2024. Novo Nordisk is the second company in recent weeks to announce a large reduction in insulin prices. Eli Lilly announced price reductions earlier in March for several of its insulin products as well as a $35 out-of-pocket cap on insulin costs for people with commercial insurance.
Read these and more top stories in endocrinology below:
Long-term studies reveal what women can expect during menopause
More than ever before, women today may have more information — and misinformation — about menopause. Read more.
Novo Nordisk to cut prices by up to 75% for some insulin products in 2024
Novo Nordisk is the latest company to announce a large reduction in insulin prices as it stated it will cut prices for multiple insulin products by up to 75% in 2024. Read more.
Sanofi announces insulin price cuts, $35 monthly cap for people with commercial insurance
Following on the heels of Eli Lilly and Novo Nordisk, Sanofi announced it will reduce the price of two of its branded insulins as well as cap out-of-pocket costs at $35 per month for people with commercial health insurance. Read more.
Age- and sex-specific values needed to avoid subclinical thyroid dysfunction misdiagnosis
Providers should use age- and sex-specific reference ranges to diagnose subclinical hypothyroidism or hyperthyroidism, especially for older adults, according to a study published in Thyroid. Read more.
Should estrogen therapy be used by breast cancer survivors?
Yes, it is time. For medicine to advance, entrenched paradigms must yield to new evidence. The widely held belief that menopausal hormone therapy causes breast cancer, and thus should never be given to breast cancer survivors, must be reassessed. Read more.